 | |
- close
- close
|
PR Newswire
Nov 4
Comment
SAN DIEGO, Nov. 4, 2009 /PRNewswire-FirstCall/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced it will report third quarter 2009 financial results after the NASDAQ Global Market closes on Monday, November 9, 2009. The next morning,
Stock Blog Hub
Nov 2
Comment
Almost all of the news in the obesity race has been made recently by three small biotech companies -- Arena Pharmaceuticals (ARNA), Vivus Inc. (VVUS) and Orexigen Therapeutics (OREX), but yesterday it was mid-cap Amylin Pharmaceuticals (AMLN) that...
FierceBiotech
Oct 27
Comment
The CEO of Arena Pharmaceuticals (ARNA) says that a second set of late-stage data on its obesity drug lorcaserin continues to show that the drug significantly outperforms a placebo in triggering weight loss and improves cardiovascular risk...
PR Newswire
Oct 27
Comment
WASHINGTON, Oct. 27, 2009 /PRNewswire-FirstCall/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) reported today data from the pivotal BLOSSOM (Behavioral modification and LOrcaserin Second Study for Obesity Management) Phase 3 trial that demonstrate
AlphaNinja
Oct 26
Comment
After a very strong open, the DJIA has dropped 140 points to current lows, down nearly half a percent. JPMorgan(JPM) and Bank of America(BAC) are the worst Dow performers, possibly due to comments from the FDIC suggesting that banks need to be...
StreetInsider.com
Oct 26
Comment
Visit StreetInsider.com at http://www.streetinsider.com/Corporate+News/Arena+Pharma+%28ARNA%29+Reports+Pivotal+BLOOM+Phase+III+data/5042483.html for the full story.
PR Newswire
Oct 25
Comment
WASHINGTON, Oct. 25, 2009 /PRNewswire-FirstCall/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) reported that data from the pivotal BLOOM (Behavioral modification and Lorcaserin for Overweight and Obesity Management) Phase 3 trial demonstrate
PR Newswire
Oct 22
Comment
SAN DIEGO, Oct. 22, 2009 /PRNewswire-FirstCall/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) announced today that the company is scheduled to provide an overview of the company at two upcoming investor conferences: -- BIOCOM Investor Conference
StreetInsider.com
Oct 12
Comment
Visit StreetInsider.com at http://www.streetinsider.com/Corporate+News/Obesity+2009+to+Feature+Multiple+Presentations+of+Arena+Pharma%27s+%28ARNA%29+Lorcaserin+/5009347.html for the full story.
Stock Blog Hub
Sep 21
Comment
Results from Arena Pharmaceuticals’ (ARNA) phase III BLOSSOM study are strikingly similar to the BLOOM study, with mean total weight loss for the 10mg lorcaserin BID group coming in at 17.0 lbs in BLOSSOM vs. 17.9 lbs in BLOOM. These equated to...
|
Topic
Top news source/blog that we're missing
Why do you recommend this news source?
|
||
more ▼WIKI ANALYSIS
WIKI ANALYSIS
 |
The article on this company has not been written yet. If you're the first person to write this article, it's a sure thing that you'll be credited as a Top Contributor. For tips on getting started, check out the sample article. |
ARNA AT A GLANCE
References
| ||||||
|
|
